{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-25-000090","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2025-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.129869+00:00","generated_at":"2026-05-19T05:09:52.704389+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"FDA clears IND for Centessa's ORX142, Phase 1 study in sleep-deprived volunteers planned","bullets":["FDA cleared IND for ORX142, a novel OX2R agonist for neurological/neurodegenerative disorders.","Phase 1 study will evaluate safety, PK, and PD (MWT, KSS) in acutely sleep-deprived healthy adults.","Clinical data from Phase 1 expected this year; study initiation imminent.","ORX142 is second orexin franchise candidate; ORX750 in Phase 2a for narcolepsy/IH."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-25-000090","json":"https://secwatch.observer/filing/0001847903-25-000090.json","markdown":"https://secwatch.observer/filing/0001847903-25-000090.md","text":"https://secwatch.observer/filing/0001847903-25-000090.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790325000090/0001847903-25-000090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790325000090/cnta-20250616.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T05:09:52.704389+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}